Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, also disclosed herein include methods of activating and enhancing the cGAS-STING response and use of an immunogenic cell death inducer with an inhibitor of a phosphodiesterase for the treatment of cancer.